A new method has been developed by the researchers to detect cancer cells much faster than the existing methods which further improves potential results in patients.
A new technique has been recently found that could detect cancer cells at many early stages by rapidly analyzing proteins that are present on cancer cells.
The existing methods to detect cancer take weeks to show positive or negative results because they require very specialized equipment and complex analysis to do the job. Meanwhile, patients start becoming relentless. Hence, the need for a better and faster method to detect cancer cells appeared.
This new method has proved to be much faster than the presently used methods as it shows results based on blood samples and increases the accuracy and reliability of potential results. It involves mixing of the biological sample with a near-infrared range emitting fluorophore.
It could be easy for doctors and scientists to measure the intensity of the light produced by the protein binding the small molecule, once a protein is allowed to interact with small molecules. These intensity rates indicate the presence of cancer in one’s body.
Darci Trader, an assistant professor of medicinal chemistry and molecular pharmacology in Purdue University’s College of Pharmacy, who led the research team said, “Pathogen or cancer cell identification often relies on culturing a sample, which can take several days. We have recently developed a method to screen one-bead-one-compound libraries against biological targets such as proteins or antibodies.”
Trader also added, “We are invested in this technology because of our passion to develop better screening techniques for a wide variety of diseases. Cancer, in particular, has touched the lives of many of our friends and families, so being able to contribute to better detection methods is very special to us.”
The existing methods only detect the proteins binding small molecules and not the extent of that binding. The new technique works by overcoming this weakness and studying the extent of these bindings. It is important to study these bindings because these provide information for diagnosing cancer and other illnesses.
Based on this information, the new method could also be effective at detecting the forms of cancer. Moreover, it is not required to monitor the activity of the biological target under study. Resultantly, increasing the types of proteins that could be screened.
This study and technology have been patented in collaboration with the Purdue Office of Technology Commercialisation.